The Global Antibiotic Resistance Partnership (GARP) was started in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries.
During the first three years, Phase 1 of GARP established national working groups in four countries: India, Kenya, South Africa, and Vietnam. The working groups’ multidisciplinary dealings with both human and animal antibiotic use have become national resources known for their expertise and linkages to the current global activities in antibiotic resistance.
GARP Phase 1 culminated at the 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance on October 3-5, 2011, in New Delhi, India. Since GARP Phase 2 began in 2012, national working groups have been established in Mozambique, Nepal, Tanzania, and Uganda.
In Phase 3, Bangladesh responded to the call to address antimicrobial resistance (AMR) by preparing a National Strategy and Action Plan for AMR. Bangladesh has taken the initiative to implement integrated activities, including a national antibiotic surveillance system and laboratory network, and collaborating with the member countries of WHO-SEARO and other countries globally. A CDDEP-supported situation analysis of AMR has attempted to analyze the scope, extent, and magnitude of the development and spread of resistant microbes and reviewed the functions, roles, and responsibilities of the stakeholders.
The Global Antibiotic Resistance Partnership is supported by the Bill & Melinda Gates Foundation and an independent public policy grant from Merck & Co., Inc., Kenilworth, NJ, USA.